{"entity":{"id":"nct07310173","kind":"trial","name":"Phase IIb Study of AST-3424 in Patients With AKR1C3-high Expressing Advanced Hepatocellular Carcinoma","aka":[],"tldr":"A phase 2 trial of Regorafenib in hepatocellular carcinoma, run by Zhejiang Hisun Pharmaceutical Co. Ltd., now recruiting.","summary":"Phase IIb Study of AST-3424 in Patients With AKR1C3-high Expressing Advanced Hepatocellular Carcinoma is a phase 2 interventional study registered as NCT07310173 by Zhejiang Hisun Pharmaceutical Co. Ltd., with 75 participants planned, started 2026-01-01 and due to reach its primary completion in 2027-10-01. Interventions recorded: AST-3424, Regorafenib Tablets. Conditions listed: HCC - Hepatocellular Carcinoma. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07310173","url":"https://clinicaltrials.gov/study/NCT07310173"}],"tags":["ctgov-ingest"],"related":[],"cancers":["hcc"],"sections":[],"technologies":[],"targets":[],"drugs":["regorafenib"],"companies":["zhejiang-hisun"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07310173","phase":"2","setting":"Phase IIb, Randomized, Active-Controlled, Parallel-Group, Multicenter Clinical Study to Evaluate the Efficacy and Safety of AST-3424 in Patients With AKR1C3-High Expressing Advanced Hepatocellular Carcinoma Who Progressed After Systemic Therapy With Immune Checkpoint Inhibitors","sponsor":"Zhejiang Hisun Pharmaceutical Co. Ltd.","enrolled":75,"outcomes":[]},"route":"/trials/nct07310173/","neighbours":{"cancer":[{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/"}],"drug":[{"id":"regorafenib","kind":"drug","name":"Regorafenib","route":"/drugs/regorafenib/"}],"company":[{"id":"zhejiang-hisun","kind":"company","name":"Zhejiang Hisun Pharmaceutical","route":"/companies/zhejiang-hisun/"}]}}